O35 Colon Carcinoma Cell Interaction with Liver Sinusoidal Endothelium Inhibits Organ-Specific Anti-Tumor Immunity via Interleukin-1-Induced Mannose Selleckchem Evofosfamide Receptor Beatriz Arteta 1 , Nerea Lasuen1, Aritz Lopategi1, Baldur Sveinbjörnsson3, Bard Smedsrod2, Fernando Vidal-Vanaclocha1 1 Department of Cell Biology and Histology, Basque Country University School of Medicine, Leioa, Bizkaia, Spain, 2 Department

of Cell Biology and Histology, Tromso University, Tromso, Norway, 3 Childhood Cancer Research Unit, KarolinskaInstitutet, Stockholm, Sweden Mannose receptor (ManR)-mediated liver sinusoidal endothelial cell (LSEC) endocytosis plays a primary role in antigen presentation and innate immunity, but its role in hepatic metastasis is unknown. We studied ManR-mediated endocytosis during C26 colorectal cancer cell interaction with LSEC and its immunological implications in the hepatic metastasis microenvironment. CFTRinh-172 Labeled mannan or ovalbumin uptake and anti-mouse ManR immunohistochemistry were used to study Selleck SC79 ManR expression and endocytosis in vivo, in vitro, and by confocal microscopy. Several IL-1 inhibitors and cyclooxygenase

(COX)-2 inhibitor Celecoxib were used to analyze the role of IL-1 and COX-2 in ManR regulation. Anti-mouse ManR antibodies and ManR knockout (ManR−/−) mice were used to identify ManR-dependent mechanisms during anti-tumor immune response of liver sinusoidal lymphocytes (LSL) interacting with tumor-activated LSEC. Both ManR expression and

endocytosis increased in tumor-activated LSEC through a two-step mechanism including: 1) Release of COX-2-dependent IL-1-stimulating factor(s) by LFA-1-expressing C26 cells in response to ICAM-1, which was over expressed and secreted Fossariinae by tumor-activated LSEC; and 2) widespread upregulation of ManR expression and endocytosis in LSEC by tumor-induced paracrine IL-1. In addition, LSL that had interacted with tumor-activated LSEC in vivo decreased their anti-tumor cytotoxicity and IFN-gamma secretion while increased IL-10 release to their supernatant ex vivo. IFN-gamma/IL-10 ratio also decreased in the hepatic blood from tumor-injected mice. Immune-suppressant effects of tumor-activated LSEC on LSL were abrogated in both LSEC from ManR−/− mice and tumor-activated LSEC given anti-mouse ManR antibodies. In summary, ICAM 1-induced tumor COX-2 led to regional anti-tumor immunity inhibition during hepatic colorectal metastasis via IL-1-induced ManR. ManR constituted a common mediator for prometastatic effects of IL-1, COX-2 and ICAM-1 in the liver. Rise of both hepatic IFNgamma:IL-10 ratio and anti-tumor cytotoxicity via ManR blockade is consistent with reported antimetastatic effects of IL-1, COX-2 and ICAM-1 inhibitors. These results support ManR as a molecular target for hepatic colorectal metastasis therapy.